M9241

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

4 competitors in Cancer of Prostate

#DrugCompanyPhaseTrials

1

PDS01ADC

NNational Cancer Institute (NCI)

Phase 2

22

Taxotere

AAvyxa

Preclinical

13

Rayos

RRoxane Laboratories

Preclinical

14

M9241

EMD Serono Research & Development Institute, Inc.

Phase 2

15

M7824

EMD Serono Research & Development Institute, Inc.

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Stereotactic Body Radiation Therapy (SBRT)1 trial

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT04327986·3 enrolled

Phase IB1 trial

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

Terminated·EMD Serono Research & Development Institute, Inc.·Phase 1·NCT02994953·52 enrolled

Cancer Of Prostate1 trial

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05361798·65 enrolled

Details

Drug Info

Related News